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Opioid receptorsmediate the actions of endogenous and exogenous opioids onmany physiological processes, including the
regulationofpain, respiratorydrive,mood, and—inthecaseofk-opioidreceptor (k-OR)—dysphoria andpsychotomimesis.
Herewe report the crystal structure of the human k-OR in complexwith the selective antagonist JDTic, arranged inparallel
dimers, at 2.9 A˚ resolution.The structure reveals important features of the ligand-bindingpocket that contribute to thehigh
affinity and subtype selectivity of JDTic for the human k-OR. Modelling of other important k-OR-selective ligands,
including the morphinan-derived antagonists norbinaltorphimine and 59-guanidinonaltrindole, and the diterpene
agonist salvinorin A analogue RB-64, reveals both common and distinct features for binding these diverse chemotypes.
Analysis of site-directedmutagenesis and ligand structure–activity relationships confirms the interactions observed in the
crystal structure, thereby providing a molecular explanation for k-OR subtype selectivity, and essential insights for the
design of compounds with new pharmacological properties targeting the human k-OR.
The four opioid receptors, m, d, k and the nociceptin/orphanin FQ
peptide receptor, belong to the class A (rhodopsin-like) c subfamily of
G-protein-coupled receptors (GPCRs)1 with a common seven-
transmembrane helical architecture, and are coupled predominantly
to heterotrimeric Gi/Go proteins. Activation of these receptors by
endogenous or exogenous ligands is linked to a number of neuro-
psychiatric sequelae, including analgesia, sedation, depression,
dysphoria and euphoria2. The three closely related subtypes, m-OR,
d-OR and k-OR, share ,70% sequence identity in their seven trans-
membrane helices (I–VII), with more variations in the extracellular
loops (ECLs) and very little similarity in their amino and carboxy
termini2. The majority of endogenous opioid peptides have a defined
preference for specific subtypes, for example, endorphins act via
d-ORs and m-ORs, whereas dynorphins preferentially activate k-ORs.
However, most exogenous and synthetic opioid ligands interact
promiscuously (see the Ki Database; http://pdsp.med.unc.edu/pdsp.
php), probably owing to the high degree of similarity among binding
pockets of opioid receptors. Although decades of focused medicinal
chemistry efforts have yielded reasonably selective ligands for all four
ORs (see the Ki Database), there remains substantial interest in the
development of subtype-selective agonists and antagonists.
Recent breakthroughs in elucidating high-resolution structures of
GPCRs in complex with small-molecule3–7 and peptide8 ligands are
providing details of their function9, leading to numerous rational
ligand discovery studies10,11. However, whereas most of these struc-
tures belong to the a subfamily of class A GPCRs1, the highly diverse
peptide-binding c subfamily is represented only by the CXCR4
chemokine receptor8; additional structural coverage is needed to
elucidate the repertoire of features12 that define the pharmacological
profile of this subfamily. The k-OR, identified based on studies with
the k-type prototypic agonist ketocyclazocine13, represents an attrac-
tive target for structure determination. Several k-OR-selective
partial agonists and antagonists have been developed as potential
antidepressants, anxiolytics and anti-addictionmedications14, whereas
a widely abused, naturally occurring hallucinogen—salvinorin A
(SalA)—was also found to be a highly selective k-OR agonist15.
Althoughmanyk-ORagonists and antagonists have not demonstrated
desirable pharmacological properties, lacking specificity or displaying
frank psychotomimetic actions in humans14,16, some have been shown
to be viable drug candidates. A k-OR ligand in early stages of
clinical development, JDTic (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-
[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]
methyl]-2-methylpropyl]-3-isoquinolinecarboxamide), was originally
designed as a novel selective k-OR antagonist17 that blocks the k-OR
agonistU50,488-induced antinociception,whilenot antagonizingm-OR
agonist-induced analgesia18. JDTic also displays robust activity in
rodent models of depression, anxiety, stress-induced cocaine relapse,
and nicotine withdrawal18,19. Here we report the crystal structure of a
human k-OR construct, k-OR–T4 lysozyme (T4L), in complex with
JDTic at 2.9 A˚ resolution. The results provide structural insights into
the atomic details ofmolecular recognition and subtype selectivity of the
k-ORand relatedORs, and should catalyse the structure-baseddesignof
advanced human k-OR agonists and antagonists with improved phar-
macological profiles and enhanced therapeutic efficacies.
Overall architecture of the k-OR
Structural studies were carried out using an engineered human k-OR
construct (see Methods and Supplementary Fig. 1) and crystallized in
cholesterol-doped monoolein lipidic cubic mesophase (see Methods).
The construct used showed pharmacological behaviour similar to that
of a native receptor expressed in HEK293T cells (Supplementary
Tables 2 and 3). Data collection and refinement statistics are shown
in Supplementary Table 1.
The structure of k-OR–JDTic was determined at 2.9 A˚ in the
P212121 space group. The asymmetric unit consists of two receptors
forming a parallel dimer (Fig. 1a). The dimer interface with,1,100 A˚2
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buried surface area is formed through contacts among helices I, II and
VIII (Fig. 1a, insert). Previously, parallel receptor dimers have been
identified in crystal structures of activated rhodopsin (involving helices
I, II and VIII)20, the b2 adrenergic receptor (b2-AR; cholesterol
mediated)3 and CXCR4 (involving helices IV, V and VI)8. Consistent
with these crystallographic data, recent biochemical studies have sug-
gested the existence of two dimerization interfaces: along helices IV and
V (sensitive to receptor activation) and along helix I (insensitive to the
state of activation)21. Although the orientations of the twoT4L copies in
the receptormonomers in one asymmetric unit differ by,60u rotation,
both copies of the receptor are highly similar (Fig. 1b) and will be
treated identically except where otherwise noted.
The main fold of the human k-OR consists of a canonical seven-
transmembrane bundle of a-helices followed by an intracellular helix
VIII that runs parallel to the membrane (Fig. 1a, b), resembling previ-
ously solved GPCR structures3–8. Structural comparison with other
GPCRs suggests that human k-OR has marked similarities in the
ECL region with CXCR4, another peptide-binding receptor in the c
subfamily. In the seven-transmembrane region, however, the k-OR
structure is closer to aminergic receptors belonging to the a subfamily
(alpha carbon root mean squared deviation (r.m.s.d.),2.3 A˚ for the
b2-AR, ,1.9 A˚ for the dopamine D3 receptor (D3R) and ,2.7 A˚ for
CXCR4). The structure reveals distinctive features of the humank-OR,
including the following. First, conformation of the extracellular end of
helix I deviates from the position observed in CXCR4, where the tip of
helix I is pulled towards the transmembrane bundle by a disulphide
bond between the N terminus and ECL3. Second, ECL2, the largest
extracellular loop of the humank-OR, forms ab-hairpin similar to that
observed inCXCR4, despite the low sequence similarity in this domain
between the two receptors. Conservation of this feature between these
peptide receptors suggests that theb-hairpin could be a commonmotif
in the ECL2 of other c subfamily receptors, where interactions between
ECL2 and their endogenous peptide ligands are deemed important for
ligand recognition and selectivity22. Third, unlike other solved non-
rhodopsin class A GPCRs that have more than one disulphide bond,
the human k-OR has only one formed between Cys 1313.25 (super-
scripts indicate residue numbering using the Ballesteros–Weinstein
nomenclature23) and Cys 210, bridging ECL2 to the end of helix III.
These two cysteines are conserved in all opioid receptors and this
disulphide bond is the canonical one shared bymost other solved class
A GPCRs. Fourth, intracellular loop 2 (ICL2) adopts slightly different
structures in the twok-ORmolecules in the asymmetric unit, involving
a two-turn a-helix in molecule B, and only a one-turn a-helix in
molecule A (Supplementary Fig. 2), possibly reflecting the conforma-
tional plasticity of this region5. Last, ECL3 of the k-OR is disordered.
Of the approximately 11 residues in this loop (residues 300–310), 6
residues in molecule A and 3 in molecule B do not have interpretable
electron density.
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Figure 1 | Crystal packing and overview of the human k-OR structure in
complex with JDTic, and comparison with the inactive CXCR4 and b2-AR
structures. a, k-OR–T4L crystal packing. The parallel dimer in one
asymmetric unit is highlighted by the insert. b, Overall architecture of k-OR–
T4L in complex with JDTic. The A molecule (yellow) and B molecule (blue)
from one asymmetric unit are aligned through the receptor part. The DRY and
NPXXYmotifs are highlighted in red and blue, respectively. JDTic is shown in a
green sphere representation and the disulphide bond is coloured orange.
c, d, Side (c) and extracellular (d) views of a structural alignment of the human
k-OR (yellow); CXCR4 (PDB accession 3ODU; magenta) and b2-AR (PDB
accession 2RH1; cyan). The graphics were created by PyMOL.
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A common feature of the class A GPCRs is the presence of a con-
served sequencemotif Asp/Glu3.49-Arg3.50-Tyr3.51 (D/ERY) located at
the cytoplasmic end of helix III. A salt bridge interaction between
Arg3.50 and Asp/Glu6.30 from the cytoplasmic end of helix VI consti-
tutes an ‘ionic lock’, which is thought to stabilize the inactive con-
formation of rhodopsin and other rhodopsin-like class A GPCRs5,24,
whereas its absence can enhance constitutive activity6,23. Although the
human k-OR lacks either of the acidic residues Asp/Glu at position
6.30, Arg 1563.50 forms a hydrogen bond to another helix VI residue,
Thr 2736.34 (Supplementary Fig. 3a) in this inactive k-OR structure,
thereby conceivably stabilizing the inactive receptor conformation.
The NPXXY motif located at the cytoplasmic side of helix VII, which
is composed of Asn 3267.49, Pro 3277.50, Ile 3287.51, Leu 3297.52 and
Tyr 3307.53 in the k-OR, is another highly conserved functional motif
that is proposed to act as one of themolecular switches responsible for
class A GPCR activation25,26. Comparison of the human k-OR with
inactive b2-AR and A2A adenosine receptor (A2AAR) structures
(Supplementary Fig. 3b) reveals a similar conformation of this motif
in these receptors, thereby supporting the hypothesis that the
observed k-OR–JDTic complex structure corresponds to the inactive
state. To establish further that JDTic stabilizes an inactive conforma-
tion, we evaluated its ability to modulate Gi/Go-mediated and
b-arrestin-mediated signalling in transfected HEK293T cells. We
found that JDTic was devoid of agonist activity at both canonical
and non-canonical pathways and completely blocked the effects of
the prototypic agonist U69593 (Supplementary Fig. 4).
The k-OR ligand-binding pocket
The k-OR ligand-binding pocket displays a unique combination of
key characteristics both shared with and distinct from those in the
chemokine and aminergic receptor families. Although the human
k-OR binding pocket is comparatively large and partially capped by
the ECL2 b-hairpin, as in CXCR4, it is alsomuch narrower and deeper
than in CXCR4 (Fig. 2c, d and Supplementary Fig. 5). In addition to a
different set of side chains lining the pocket, the shape differences
result from an approximately 4.5 A˚ inward shift of the extracellular
tip of helix VI in the k-OR as compared to CXCR4. The electron
density clearly shows the position of the JDTic ligand (Supplemen-
tary Fig. 6), which reaches deep into the pocket to form ionic inter-
actions with the Asp 1383.32 side chain (Fig. 2a). The Asp3.32 residue is
conserved in all aminergic GPCRs, thereby having a critical role in the
selectivity of aminergic receptors towards protonated amine-containing
ligands. Likewise, Asp3.32 is conserved in all opioid receptors, and
modelling and mutagenesis studies27 suggest that it has an essential
role in anchoring positively charged k-OR ligands.
Structural basis of JDTic selectivity
JDTic, developed as a derivative of the trans-(3R,4R)-4-(3-
hydroxyphenyl)-3,4-dimethyl-1-piperidine scaffold17, has exceptionally
high affinity (Ki5 0.32 nM), potency (Ki5 0.02 nM in GTPcS
assays)17,28, long duration of action and a more than 1,000-fold selec-
tivity for the human k-OR as compared to other opioid receptor sub-
types28. Extensive structure–activity relationship (SAR) analyses
performed on JDTic analogues have yielded important insights into
key determinants of JDTic activity28–30, although reliable identification
of the interactionmode(s) and contact residues of these ligands has not
been feasible without a receptor crystal structure.
The crystal structure of k-OR–JDTic shows a tight fit of the ligand
in the bottom of the binding cleft (Fig. 2a), forming ionic, polar and
extensive hydrophobic interactions with the receptor (Fig. 2b). The
protonated amines in both piperidine and isoquinolinemoieties of the
ligand form salt bridges to the Asp 1383.32 side chain (3.0 and 2.8 A˚
nitrogen–oxygen for molecule A, and 2.7 and 2.3 A˚ for molecule B,
respectively). The piperidine amine is part of the original trans-
(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine scaffold and is
essential for opioid receptor antagonist activity31. SAR studies of
JDTic analogues show that the isoquinoline nitrogen can be replaced
by carbon, oxygen or sulphur atoms with only a ,10- to 50-fold
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Figure 2 | Binding of the high-affinity selective
antagonist JDTic in the human k-OR crystal
structure. a, Conformation of the binding pocket
with JDTic shown by sticks with yellow carbons.
The protein is displayed in cartoon representation
looking down from the extracellular side, with the
22 contact residues within 4.5 A˚ from the ligand
shown by white sticks. The pocket surface is shown
as a semitransparent surface coloured according to
binding properties (green: hydrophobic; blue:
hydrogen-bond donor; red: hydrogen-bond
acceptor). Salt bridges and hydrogen bonds are
shown as dotted lines. Structured water molecules
are shown as large magenta spheres. b, Diagram of
ligand interactions in the binding pocket side
chains at 4.5 A˚ cut-off. Salt bridges are shown in red
and direct hydrogen bonds in blue dashed lines.
Ballesteros–Weinstein numbering is shown as
superscript. Residues that vary among the m-OR,
d-OR and k-OR subtypes are highlighted in cyan,
and residue Asp 1383.32 implicated in k-OR-ligand
binding bymutagenesis data, is highlighted orange.
c–e, Side views of the sliced binding pocket in
k-OR–JDTic (c), CXCR4–IT1t (d) and b2-AR–
carazolol (e) complexes. The pocket surfaces are
coloured as in panel a, the protein interior is black
and the extracellular space is white. Ligands are
shown as capped sticks with carbons coloured
yellow (JDTic), magenta (IT1t) and cyan
(carazolol). Asp3.32 side chains in k-OR–JDTic and
b2-AR–carazolol complexes are shown by thin
sticks with grey carbons. The graphics were
prepared using the ICM molecular modelling
package (Molsoft LLC).
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reduction in affinity30. Similar to the observed JDTic conformation in
the k-OR–JDTic complex, a V-shaped conformation was found in the
small molecule X-ray crystal structure of JDTic, which showed its
amino groups coordinating a water molecule (Supplementary Fig.
7a). Although several rotatable bondswithin the JDTicmolecule allow
for the sampling of different conformations (see Supplementary Fig.
7b) and facilitate the ligand passage through the narrow binding
pocket entrance, the anchoring-type interaction of two amino groups
with Asp 1383.32 probably fixes the ligand in this characteristic V
shape.
SAR studies have also underscored the importance of the distal
hydroxyl groups on both the piperidine and isoquinoline moieties
of JDTic, the removal of which did result in about a 100-fold reduction
of affinity. A much smaller effect was observed upon methylation of
these hydroxyls or their replacement by other polar groups28. These
SAR results suggest the importance of water-mediated interactions
between these two hydroxyl groups and the receptor. Indeed,
although the crystal structure does not show direct hydrogen bonding
with the receptor for both hydroxyl groups, there is clear electron
density for several structured watermolecules thatmediate their polar
interactions (Supplementary Fig. 6).
The k-OR structure provides important clues for understanding the
structural basis of the exceptional subtype selectivity of JDTic. Among
many extensive contacts, JDTic interacts with four residues in the
binding pocket that differ in other closely related opioid receptors,
which are thought to contribute to the subtype selectivity of JDTic
and other k-OR-selective ligands32 (human m-OR and d-OR amino
acids are shown inparentheses, respectively): Val 1082.53 (Ala andAla),
Val 1182.63 (Asn and Lys), Ile 2946.55 (Val and Val) and Tyr 3127.35
(Trp and Leu) (Fig. 2b and Supplementary Fig. 8). Analysis of JDTic
binding into k-OR-based m-OR and d-OR homology models, as well
as JDTic SAR results17,28,30 (Supplementary Fig. 9), suggest that all
described residues can contribute to the JDTic selectivity profile.
Thus, changes in the Val 1182.63 side chain, where larger hydrophilic
residues Asn2.63 and Lys2.63 are found in the human m-OR and d-OR,
respectively, are likely to introduce unfavourable contacts with JDTic.
Additionally, changing Tyr 3127.35 to the Trp7.35 and Leu7.35 residues
found in the human m-OR and d-OR, respectively, is likely to result in
the loss of an important polar interaction with the JDTic amide. The
remaining two hydrophobic side-chain replacements, Val to Ala at
position 2.53 and Ile to Val at position 6.55, may cause a reduction
of the hydrophobic contact between JDTic and the receptor.
The isopropyl group of JDTic reaches deep into the orthosteric
pocket to form a hydrophobic interaction with a conserved
Trp 2876.48 side chain, possibly having a critical role in the pharmaco-
logical properties of this ligand. Trp6.48 is thought to be a key part of
the activationmechanism inmany class A GPCRs, including rhodop-
sin26 and the A2AAR25, and similar hydrophobic contacts have been
implicated in blocking activation-related conformational changes in
the dark state visual rhodopsin by 11-cis retinal, and by inverse ago-
nists in the A2AAR and D3R.
Binding of k-OR-selective morphinans
Prior mutagenesis and modelling studies suggested that many small-
molecule opioid ligands can interact with the k-OR, as well as with the
m-OR and d-OR, by forming a salt bridge with the highly conserved
Asp3.32 (refs 33, 34). This is consistent with our mutagenesis studies
(Supplementary Table 3) and flexible docking35 of a series ofmorphine
analogues, including selective k-OR antagonists norbinaltorphimine
(nor-BNI) and 59-guanidinonaltrindole (GNTI) (Fig. 3 and Sup-
plementary Fig. 10). To assess the compatibility of these bulky and rigid
ligands with the observed k-OR protein backbone conformation, we
performed global energy optimizations of nor-BNI and GNTI in the
binding cavity of k-OR, keeping side chains of the binding pocket fully
flexible. Multiple independent runs consistently resulted in low energy
conformations with essentially identical poses and receptor contacts
for the common naltrexone moieties of both nor-BNI and GNTI
(r.m.s.d. 0.85 A˚). In addition to a highly complementary van der
Waals interface, both compounds formed an amino group salt bridge
to theAsp 1383.32 side chain and a hydrogen bond to theTyr 1393.33 side
chain, both of which are important anchoring points for binding of
morphine-based ligands, as supported by previous mutagenesis
studies34.
Moreover, unlike JDTic, both nor-BNI andGNTI compounds have
a second basic moiety located more than 10 A˚ away from the first
amino group (the second morphine moiety in nor-BNI and the
guanidine moiety in GNTI). In the predicted models of k-OR–
nor-BNI/GNTI complexes, these additional amino groups of both
ligands form a salt bridge with Glu 2976.58 located at the entrance to
the ligand-binding pocket, which was previously characterized as a
residue critical for subtype selectivity of k-OR-selective morphinan
derivatives36. This interaction is also supported by our mutagenesis
results (Supplementary Table 3), where a Glu297Ala mutation
induced a significant drop in both nor-BNI andGNTI binding affinity,
but did not affect JDTic affinity. Hydrophobic interactions at the
k-OR-specific residue Ile 294 were also found for both nor-BNI and
GNTI; consistent with our mutagenesis results (Supplementary
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Figure 3 | Putative interaction modes of morphine-based high-affinity
k-OR-selective antagonists nor-BNI and GNTI. a, b, Interaction modes of
nor-BNI (a) and GNTI (b). Ligands are depicted as capped sticks with green
carbons, and contact side chains of the receptor within 4 A˚ from the ligand are
shown with grey carbons. Key hydrogen bonds and salt bridges are indicated
with small cyan spheres and residues unique to the k-OR are labelled in blue.
Residue Asp 1383.32, which also shows critical impact on GNTI and nor-BNI
binding in mutagenesis studies, is highlighted in red. Ballesteros–Weinstein
residue numbers are shown under the k-OR residue numbers. The graphics
were prepared using the ICM molecular modelling package (Molsoft LLC).
RESEARCH ARTICLE
3 3 0 | N A T U R E | V O L 4 8 5 | 1 7 M A Y 2 0 1 2
Macmillan Publishers Limited. All rights reserved©2012
Table 3) and suggesting that Ile 294 may also be important for
developing human k-OR-subtype-selective morphinan derivatives.
Additional polar interactions with k-OR-specific residues, Glu 209
and Ser 211 in ECL2, are found for nor-BNI, which may further
enhance the k-OR selectivity of this bulky ligand. Another side chain
of the pocket, His 2916.52, which is involved in the highly conserved
aromatic cluster around Trp6.48 and thought to have a critical role in
the receptor activation process37, forms hydrophobic contacts with
JDTic, nor-BNI and GNTI. His 2916.52 can be mutated to another
aromatic residue, phenylalanine, without disrupting binding of
these antagonists (Supplementary Table 3). The non-conservative
His2916.52Lys mutation, however, abolished binding of all tested
ligands, probably because of the disruption of the aromatic cluster
induced by the lysine side chain. Interestingly, the cyclopropyl moiety
of both nor-BNI and GNTI in these binding poses has the same
position as the isopropylmoietyof JDTic,makinghydrophobic contact
with the conserved residue Trp 2876.48. This cyclopropyl moiety is
generally implicated in conversion of opioid agonists into antagonists
(for example, agonist oxymorphone into antagonist naltrexone), and
this effect may be partially explained by a direct interaction with the
Trp 2876.48 side chain.
Overall, these structure-based docking results support the ‘message–
address’ model38 for morphine-based ligands nor-BNI and GNTI36,
which points to Glu 2976.58 as a key side chain that controls k-OR
selectivity by anchoring the ‘address’ moieties of these compounds.
The crystal structure of the k-OR–JDTic complex (Figs 2 and 3),
however, demonstrates that evenwithout an ‘address’ interactionwith
Glu 2976.58, more than a 1,000-fold subtype-selectivity to k-OR can be
achieved for JDTic and some of its derivatives. Importantly, then, the
message–address hypothesis does not uniformly apply to all k-OR-
selective antagonists.
Binding of salvinorins
SalA, a naturally occurring diterpene from the widely abused
hallucinogenic plant Salvia divinorum, represents an exceedingly
potent (half-maximum effective concentration (EC50)5 1 nM) and
selective k-OR agonist (.1,000-fold)15. SalA is unique compared to
other k-OR ligands in that it lacks a charged or polar nitrogen atom to
anchor it in the binding pocket. Extensive site-directed mutagenesis,
substituted cysteine-accessibilitymutagenesis (SCAM)andSAR studies
on SalA and its analogues have been performed, indicating (among
others) that the 2-acetoxy moiety interacts with Cys 3157.38 (ref. 39).
Possible modes of interaction between the cysteine-reactive and ultra-
potent agonist and SalA analogue 22-thiocyanatosalvinorin A (RB-64;
Ki5 0.59 nM; EC505 0.077 nM)39, and the human k-OR structure
were thus evaluated. Exposure of k-OR to RB-64 produces irreversibly
bound, wash-resistant adducts that are tethered to Cys 3157.38 (ref. 39).
As the thiocyanate group contains two electrophilic centres, two
distinct adducts may be formed, increasing the mass by either 463 or
431 AMU. Docking studies using GOLD40 predict that the salvinorin
2-position can access Cys 3157.38 while maintainingmany of the inter-
actions implicated by site-directed mutagenesis for SalA, providing a
possible mechanism for the formation of the k-OR–RB-64 adduct
(Fig. 4, Supplementary Tables 4 and 5, and Supplementary Figs 11
and 12). Additionally, the docking results serve as amodel of the initial
recognition process of SalA-related agonists of the human k-OR in an
inactive state, although additional studies will be needed to fully
elucidate the nature of the SalA-induced activation mechanism.
Conclusions
The k-OR–JDTic crystal structure has uncovered a combination of key
features sharedwith chemokine andaminergicGPCRsalongwithunique
structural details characteristic of the opioid subfamily.Thehumank-OR
was crystallized as aparallel dimerwith contacts involvinghelices I, II and
VIII. Although the existence of GPCR dimers in vivo and their physio-
logical relevance remain highly debatable, several distinct potential dimer
interfaces are starting to emerge from crystallographic and biochemical
studies. Such multiple dimerization interfaces may serve to support dif-
ferent functional pathways, as well as to promote oligomeric assembly of
GPCRs. Analysis of ligand–receptor interactions has revealed important
molecular details of the exceptionally high affinity and subtype selectivity
of JDTic, a small-molecule antagonist with a broad therapeutic potential.
The elucidation of a large binding cavity with a multitude of potential
anchoring points begins to explain both the broad structural diversity of
drugs targeting the human k-OR and differences in their receptor inter-
action modes, as supported by differential effects of various site-directed
mutations on the binding properties of chemically diverse prototypic
ligands. The human k-OR structure provides a long anticipated
molecular framework for understanding opioid drug action, and thereby
affords valuable new opportunities for the structure-based discovery of
new drugs with ideal pharmacological properties.
METHODS SUMMARY
k-OR–T4L was expressed in Spodoptera frugiperda (Sf9) cells. Ligand-binding and
functional assays were performed as described in Methods. Receptor–ligand com-
plexes were solubilized fromwashed Sf9membranes using 1% (w/v) n-dodecyl-b-D-
maltopyranoside (DDM) and 0.2% (w/v) cholesteryl hemisuccinate (CHS), and
purified by immobilized metal ion affinity chromatography (IMAC), followed by
reverse IMAC after cleaving N-terminal Flag–103His tags by His-tagged tobacco
etch virus (TEV) protease. The purified protein solution was mixed withmonoolein
and cholesterol in a ratio of 40%:54%:6% (w/w) to form lipidic cubic phase (LCP)
from which the receptor was crystallized. Crystals were grown at 20 uC in 45nl
protein-laden LCP boluses overlaid by 800nl of precipitant solutions as described
in Methods. Crystals were harvested from the LCPmatrix and flash frozen in liquid
nitrogen. X-ray diffraction data were collected on the 23ID-B/D beamline (GM/CA
CAT) at the Advanced Photon Source, Argonne, using a 10mm minibeam at a
wavelength of 1.0330 A˚. Data collection, processing, structure solution and refine-
ment are described in Methods. Modelling of JDTic analogues and k-OR-selective
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Figure 4 | Model of covalently bound RB-64. a, b, Putative binding mode of
the RB-641463AMU (a) and the RB-641431AMU (b) adduct. Residues within
4 A˚ of the ligand are shown. Ligand, capped sticks/cyan carbons; k-OR side
chains, capped sticks; hydrogen bonds, small green spheres; k-OR-unique
residues are labelled in blue. Ballesteros–Weinstein residue numbers are shown
under the k-OR residue numbers. The graphics were prepared using the ICM
molecular modelling package (Molsoft LLC).
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morphine derivatives nor-BNI and GNTI was performed using ICM-Pro; SYBYL-
X 1.3 and GOLD Suite 5.1 were used to model RB-64 complexes, as described in
Methods.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Protein engineering for structural studies. Human k-OR was engineered for
structural studies by fusing lysozyme from T4 phage (T4L) into ICL3 (Gly 261–
Arg 263) and further modified by N/C-terminal truncations (DGlu2–Ala42,
DArg359–Val380) and a single point mutation Ile1353.29Leu (see Sup-
plementary Information). The resulting k-OR–T4L construct was subsequently
expressed in baculovirus-infected Spodoptera frugiperda (Sf9) insect cells.
Generation of k-OR constructs for Sf9 expression. The human k-OR (I135L)
cDNA provided by the NIMH Psychoactive Drug Screening Programwas cloned
into a modified pFastBac1 vector (Invitrogen), designated as pFastBac1-833100,
which contained an expression cassette with a haemagglutinin (HA) signal
sequence followed by a Flag tag, a 103His tag3, and a TEV protease recognition
site at the N terminus before the receptor sequence. Subcloning into the
pFastBac1-833100 was achieved using PCR with primer pairs encoding restric-
tion sites BamHI at the 59 and HindIII at the 39 termini of k-OR wild type with
subsequent ligation into the corresponding restriction sites found in the vector.
The k-OR–T4L gene, based on the human k-OR (I135L) and cysteine-free
lysozyme from bacteriophage T4 (T4L C54T, C97A) sequences41, included the
following additional features: (1) residue Ser 262 at ICL3 of k-OR was deleted by
using standard QuickChange PCR; (2) Asn 2–Tyr 161 of T4L were inserted
betweenGly 261 andArg 263within the ICL3 region; and (3) N-terminal residues
2–42 and C-terminal residues 359–380 of k-OR were truncated.
Expression and purification of k-OR constructs. High-titre recombinant
baculovirus (.109 viral particles per ml) was obtained using the Bac-to-Bac
Baculovirus Expression System (Invitrogen) as previously described5,8. 25mM
of the antagonist naltrexone (NTX) and 5% Protein Boost Additive (PBA) were
added to the system during expression. Cell suspensions were incubated for 4
days while shaking at 27 uC. Production of high-titre baculovirus stocks was
performed as described before5,8. Sf9 cells at a cell density of 2–33 106 cellsml21
were infected with P2 virus at a m.o.i. (multiplicity of infection) of 2. Cells were
harvested by centrifugation at 48 h post-infection and stored at280 uC until use.
Insect cell membranes were disrupted by thawing frozen cell pellets in a hypo-
tonic buffer containing 10mM HEPES, pH 7.5, 10mM MgCl2, 20mM KCl and
EDTA-free complete protease inhibitor cocktail tablets (Roche). Extensive wash-
ing of the raw membranes was performed by repeated centrifugation in the same
hypotonic buffer (two to three times), and then in a high osmotic buffer contain-
ing 1.0M NaCl, 10mM HEPES, pH 7.5, 10mMMgCl2, 20mM KCl and EDTA-
free complete protease inhibitor cocktail tablets (three to four times), thereby
separating soluble and membrane associated proteins from integral transmem-
brane proteins.
Washed membranes were resuspended into buffer containing 40mM NTX,
2mgml21 iodoacetamide, 150mM NaCl and EDTA-free complete protease
inhibitor cocktail tablets, and incubated at 4 uC for 1 h before solubilization.
The membranes were then solubilized in 50mM HEPES, pH 7.5, 150mM
NaCl, 1% (w/v) n-dodecyl-b-D-maltopyranoside (DDM, Anatrace), 0.2% (w/v)
cholesteryl hemisuccinate (CHS, Sigma) and 20 mM NTX for 3 h at 4 uC. The
supernatant was isolated by centrifugation at 160,000g for 40min, and incubated
in 30mM buffered imidazole (pH 7.5), 1M NaCl with TALON IMAC resin
(Clontech) overnight at 4 uC. After binding, the resin was washed with 10 column
volumes of Wash I Buffer (50mM HEPES, pH 7.5, 800mM NaCl, 10% (v/v)
glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 10mM ATP, 10mM MgCl2 and
50 mM JDTic), followed by 6 column volumes of Wash II Buffer (50mMHEPES,
pH 7.5, 500mMNaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS,
50mM imidazole and 50 mM JDTic). The protein was then eluted by 3 column
volumes of Elution Buffer (50mM HEPES, pH 7.5, 300mM NaCl, 10% (v/v)
glycerol, 0.03% (w/v) DDM, 0.006% (w/v) CHS, 250mM imidazole and 50mM
JDTic). PDMiniTrapG-25 column (GEhealthcare)wasused to remove imidazole.
The protein was then treated overnight with His-tagged AcTEV protease
(Invitrogen) to cleave the N-terminal His-tag and Flag-tag. AcTEV protease and
cleavedN-terminal fragment were removed by TALON IMAC resin incubation at
4 uC for 2 h for binding. The tag-less protein was collected as the TALON
IMAC column flow-through. The protein was then concentrated to 40mgml21
with a 100 kDa molecular weight cut-off Vivaspin centrifuge concentrator (GE
healthcare). Protein purity and monodispersity were tested by SDS–PAGE and
analytical size-exclusion chromatography (aSEC). Typically, the protein purity
exceeded 95%, and the aSEC profile showed a single peak, indicative of receptor
monodispersity.
Lipidic cubic phase crystallization. Protein samples of k-OR in complex with
JDTic were reconstituted into lipidic cubic phase (LCP) by mixing with molten
lipid in a mechanical syringe mixer42. LCP crystallization trials were performed
using an NT8-LCP crystallization robot (Formulatrix) as previously described43.
96-well glass sandwich plates (Marienfeld) were incubated and imaged at 20 uC
using an automated incubator/imager (RockImager 1000, Formulatrix). Initial
crystal hits were found from precipitant condition containing 100mM
sodium citrate pH 6.0, 30% (v/v) PEG400, 400mM potassium nitrate. After
extensive optimization, crystals of 30 mm3 10 mm3 5 mm to 60 mm3 20 mm
3 10 mm size were obtained in 100mM sodium citrate pH 5.8–6.4, 28–32%
(v/v) PEG400, 350–450mM potassium nitrate. Crystals were harvested directly
from LCP matrix using MiTeGen micromounts and flash frozen in liquid
nitrogen.
Data collection, structure solution and refinement.X-ray data were collected at
the 23ID-B/D beamline (GM/CA CAT) at the Advanced Photon Source,
Argonne, using a 10 mm minibeam at a wavelength of 1.0330 A˚ and a
MarMosaic 300 CCD detector. Most crystals were invisible after flash freezing
in liquid nitrogen, and a similar alignment and data-collection strategy was
followed as previously described44. Among the several hundred crystal samples
screened,most crystals diffracted to 2.8–3.5 A˚ resolutionwhen exposed to 1–5 s of
unattenuated beam using 1u oscillation. Data collection was limited to 5–10
frames per crystal, due to the fast onset of radiation damage in the microcrystals.
Data were integrated, scaled and merged using HKL200045. A 97% complete data
set ofk-OR–T4L/JDTic (space groupP212121) at 2.9 A˚ resolutionwas obtained by
merging data collected from 60 crystals. Initial phase information was obtained
by molecular replacement with the program PHASER46 using two independent
search models of the polyalanine seven-transmembrane a-helices of CXCR4–
IT1t (PDB accession 3ODU) and ensemble T4L models of b2-AR–T4L (PDB
accession 2RH1), A2AAR–T4L (PDB accession 3EML), CXCR4–T4L (PDB
accession 3ODU), D3R–T4L (PDB accession 3PBL) and H1R–T4L (PDB acces-
sion 3RZE). Electron density refinement was performed with REFMAC547,
autoBUSTER48, and PHENIX49 followed by manual examination and rebuilding
of the refined coordinates in the program COOT50 using both j2Foj2 jFcj and
jFoj2 jFcjmaps, as well as omit maps. The final model includes 287 residues of A
chain (Ser 55–Gly 261, Arg 263–Ser 301, Ala 307–Pro 347) and 288 residues of B
chain (Ser 55–Gly 261, Arg 263–Gly 300, Ser 305–Pro 347) of the k-OR, and resi-
dues Asn 2–Tyr 161 of both A and B chains of T4L.
Ligand-binding assay. Membrane preparations, radioligand binding assays
using 3H-diprenorphine and data analyses were performed as previously
described39.
Modelling of high-affinity analogues of JDTic andmorphine.Docking of high-
affinity k-OR-specific ligands was performed using an all-atom flexible receptor
docking algorithm in ICM-Pro (MolSoft LLC) molecular modelling package as
described previously35. Internal coordinate (torsion) movements were allowed in
the side chains of the binding pocket, defined as residues within 10 A˚ distance of
JDTic in the crystal structure. Other side chains and the backbone of the protein
were kept as in the crystal structure. An initial conformation for each of the ligands
was generated by Cartesian optimization of the ligand model in Merck Molecular
Force Field. Docking was performed by placing the ligand in a random position
within 5 A˚ from the entrance to the binding pocket and global conformational
energy optimization of the complex39,40. To facilitate side-chain rotamer switches
in flexible k-OR models, the first 106 steps of the Monte Carlo (MC) procedure
used ‘soft’ vanderWaals potentials andhighMCtemperature, followedby another
106 stepswith ‘exact’ vanderWaalsmethod andgradually decreasing temperature.
A harmonic ‘distance restraint’ applied between an amino group of the ligand and
carboxyl of Asp138 side chain in the initial 106 steps was removed in the final 106
steps. At least 10 independent runs of the docking procedure were performed for
each k-OR ligand. The docking results were considered ‘consistent’ when at least
80% of the individual runs resulted in conformations clustered within a r.m.s.d. of
,1 A˚ to the overall best energy pose of the ligand. All calculations were performed
on a 12-core Linux workstation.
Modelling of RB-64. Modelling of RB-64 was performed using SYBYL-X 1.3
(Tripos) and GOLD 5.1 (Cambridge Crystallographic Data Centre)40. Default
parameters were used except where noted. The structures of RB-64 and its
k-OR complexes were energy minimized using the Tripos Force Field
(Gasteiger–Hu¨ckel charges, distance-dependent dielectric constant e5 4, non-
bonded interaction cut-off5 8 A˚, energy gradient termination5 0.05 kcal/
(mol3 A˚)). The k-OR C3157.38 x1 torsion angle was modified (x15160.0u),
orienting the sulfhydryl group towards the binding cavity. A docking distance
constraint was used (C315 SG atom to thiocyanate sulphur atom distance, 2.0–
6.0 A˚; spring constant5 5.0). The Q1152.60, D1383.32, I2906.51, I2946.55, Y3137.36
and I3167.39 side chains were allowed to flex via rotamer library. The GoldScore
fitness function was used with early termination disabled for 30 genetic algorithm
runs. Poses were selected based on their GoldScore and ability to explain the
relevant observed biochemical data. Stereochemical quality was assessed using
PROCHECK.
41. Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural
insights into b2-adrenergic receptor function. Science 318, 1266–1273 (2007).
ARTICLE RESEARCH
Macmillan Publishers Limited. All rights reserved©2012
42. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic
mesophases. Nature Protocols 4, 706–731 (2009).
43. Cherezov, V., Peddi, A., Muthusubramaniam, L., Zheng, Y. F. & Caffrey, M. A robotic
system for crystallizing membrane and soluble proteins in lipidic mesophases.
Acta Crystallogr. D 60, 1795–1807 (2004).
44. Cherezov, V. et al. Rastering strategy for screening and centring of microcrystal
samples of human membrane proteins with a sub-10 mm size X-ray synchrotron
beam. J. R. Soc. Interface 6 (Suppl. 5), S587–S597 (2009).
45. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in
oscillation mode. Methods Enzymol. 276, 307–326 (1997).
46. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658–674
(2007).
47. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240–255
(1997).
48. Bricogne, G, et al. BUSTER v. 2.8.0 (Global Phasing, 2009).
49. Adams, P. D, et al. PHENIX: a comprehensive Python-based system for
macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
50. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of
Coot. Acta Crystallogr. D 66, 486–501 (2010).
RESEARCH ARTICLE
Macmillan Publishers Limited. All rights reserved©2012
